Megakaryocytic hyperplasia is a finding, not a disease: the bone marrow holds more platelet-making cells than usual. Most often it reflects the marrow working harder to replace platelets that are being lost, used or destroyed, and iron deficiency or inflammation can do the same. It is also one of the main features of a group of chronic marrow cancers, so the report is a starting point rather than a diagnosis.1The Hematology Journal. Bonemarrowhistopathologyandbiologicalmarkersasspecificcluestothedifferential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia What separates a harmless cause from a serious one is less how many of these cells there are than what they look like and what else is going on in the blood.
Why the Marrow Makes More Platelet-Making Cells
Megakaryocytes are very large bone marrow cells that break apart to release platelets, the cell fragments that help blood clot. Their growth is controlled mainly by a hormone carried in the blood.2PubMed. Thrombopoietin, the Mpl ligand, is essential for full megakaryocyte development It acts on nearly every step, from early stem cells to the mature cell that sheds platelets.3PubMed Central. The molecular mechanisms that control thrombopoiesis The more of it circulating, the more these cells multiply and mature.4PubMed. Megakaryocyte development and platelet production So when platelets fall, the marrow makes more of them, larger ones, and ones with more DNA.5PubMed. Milestones in understanding platelet production: a historical overview
On a biopsy report, “hyperplasia” simply means more cells than expected for the patient’s age. The pathologist also describes size, shape and clustering, and the comment section often hints whether the picture looks reactive or neoplastic.
A biopsy is usually ordered because platelets were persistently too high or too low, and sometimes for unexplained anaemia or high blood counts. It is a snapshot of one day and cannot say how long the increase has been there or why it started, so the report is read alongside the blood count from around the same time.
Reactive Causes, Platelet Loss, Iron Deficiency and Inflammation
In immune thrombocytopenia (ITP), the body’s own antibodies and immune cells destroy platelets, so they don’t last as long.6PubMed Central. Morphologic evaluation of megakaryocytes in immune thrombocytopenia patients older than 80 years The marrow often responds with more megakaryocytes, and these cells carry extra DNA.7PubMed. The relation of megakaryocyte ploidy to platelet volume Low platelets with plenty of megakaryocytes suggests platelets are being destroyed or used up rather than not being made. The platelets in the blood also tend to be larger than average, which your blood count report may list as a high MPV (mean platelet volume).8PubMed. The relation of megakaryocyte ploidy to platelet volume
Iron deficiency anaemia is linked to higher platelet production.9Blood. Megakaryocytopoiesis in Experimental Iron Deficiency Anemia Low iron in the marrow nudges shared early cells toward becoming megakaryocytes instead of red cells.10PubMed Central. Low iron promotes megakaryocytic commitment of megakaryocytic-erythroid progenitors in humans and mice In animal studies, moderate iron deficiency sped up megakaryocyte turnover, while severe deficiency produced larger cells with more DNA.11Blood. Megakaryocytopoiesis in Experimental Iron Deficiency Anemia Treating the deficiency is expected to let this response settle.
Acute inflammation can quickly activate a reserve of megakaryocyte precursors to replace platelets used up during the illness.12Cell Stem Cell. Inflammation-Induced Emergency Megakaryopoiesis Driven by Hematopoietic Stem Cell-like Megakaryocyte Progenitors In reactive high platelet counts, platelets tend to be small and the megakaryocytes carry less DNA.13PubMed. The relation of megakaryocyte ploidy to platelet volume
Doctors check for other everyday triggers too. Recent surgery, heavy bleeding or an injury raises platelet demand, and the marrow makes more platelet-making cells for a while. Long-term inflammatory conditions such as rheumatoid arthritis or inflammatory bowel disease can keep the count and the marrow response elevated. Removing the spleen raises platelet counts because the spleen normally stores and clears some platelets, and the effect can persist. Recovery after chemotherapy or a platelet drop can also produce a temporary rebound. A reactive pattern on the report looks fairly plain: increased megakaryocytes that are normal in shape, no tight clusters or bizarre nuclei, no marrow scarring, and negative genetic tests for driver mutations.
Myeloproliferative Neoplasms, ET, Polycythemia Vera and Myelofibrosis
Myeloproliferative neoplasms (MPNs) are slow-growing blood cancers in which the marrow makes too many blood cells. Most people with essential thrombocythemia (ET) carry a JAK2 mutation, almost a quarter carry CALR, and a few carry MPL.14MPN Research Foundation. Essential Thrombocythemia (ET) The changes send nonstop signals telling the marrow to make platelets.15MPN Research Foundation. Essential Thrombocythemia (ET) MPN megakaryocytes also multiply faster and die less often than normal ones.16PubMed Central. The role of megakaryocytes in myelofibrosis
The genes make proteins that act like a switch in the cell’s growth-signalling pathway, and the mutations leave that switch stuck on. Because the signal no longer depends on the platelet hormone, the marrow keeps producing cells when there is no need. The mutation is acquired during life in marrow cells rather than inherited, so it is not usually passed to children.
- Essential thrombocythemia: more, larger mature megakaryocytes with many-lobed nuclei, gathered in small groups near blood channels.17The Hematology Journal. Bonemarrowhistopathologyandbiologicalmarkersasspecificcluestothedifferential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia
- Polycythemia vera: the same increase, often even more marked, with mixed tiny and giant forms and a very crowded marrow.18The Hematology Journal. Bonemarrowhistopathologyandbiologicalmarkersasspecificcluestothedifferential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia
- Primary myelofibrosis: odd, immature large cells with clumsy, “cloud-like” nuclei that are rarely seen in ET or PV.19PubMed Central. A Review of the Pathological and Molecular Diagnosis of Primary Myelofibrosis
- Myelofibrosis, also: whole megakaryocytes may slip into the marrow’s blood channels.20Haematologica. Is it primary myelofibrosis or chronic megakaryocytic leukemia?
The three conditions overlap, so the diagnosis rests on blood counts, gene results and marrow appearance together. ET mainly raises platelets, while polycythemia vera mainly raises red cell numbers, often with other counts up as well. Myelofibrosis is distinguished by scarring and its immature-looking cells, and some people begin with a milder phase that later progresses. Because the patterns come in shades, difficult cases are often reviewed by pathologists experienced in these diseases. The diagnosis matters because the JAK2 mutation itself raises clot risk, even in people with normal blood counts.21PubMed Central. Low-Risk Essential Thrombocythemia: A Comprehensive Review
ET and PV are often managed for years with regular blood counts and medicines, and some people need little more than monitoring and low-dose aspirin if their doctor advises it. Myelofibrosis is more serious and generally needs closer follow-up by a specialist.
Certain symptoms are worth reporting: unexplained headaches, vision changes or burning hands and feet; leg swelling or chest pain that could signal a clot; and night sweats, weight loss or a swollen belly from a large spleen.
Myelodysplastic Syndrome With 5q Deletion
Myelodysplastic syndromes (MDS) are marrow disorders that produce faulty blood cells. In MDS with an isolated 5q deletion, megakaryocytes are increased.22PubMed Central. Images from the Haematologica Atlas of Hematologic Cytology: myelodysplastic syndrome with isolated del(5q) But they are normal-sized or small, with a single round, unlobed nucleus.23PubMed Central. Images from the Haematologica Atlas of Hematologic Cytology: myelodysplastic syndrome with isolated del(5q) This usually comes with anaemia with large red cells, and sometimes a high platelet count.24PubMed Central. Images from the Haematologica Atlas of Hematologic Cytology: myelodysplastic syndrome with isolated del(5q) Small simple cells like these point away from ET and polycythemia vera, whose cells are large and many-lobed.
A chromosome test on the marrow sample looks for the missing piece of chromosome 5, and this result is central to the diagnosis. The proportion of immature blast cells must also be low, under 5% in the marrow, for this type to apply. Naming it matters because it often responds well to a particular treatment, so it is managed differently from other MDS.
Medicines That Raise Megakaryocyte Numbers
Drugs that act like the platelet hormone, such as romiplostim and eltrombopag, are used to raise low platelet counts. They bind to the same receptor as the natural hormone, so the marrow reads them as a signal to make more platelets. In people with ITP on these drugs, megakaryocyte numbers rose in most, with many giant, heavily lobed cells.25Modern Pathology. Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities These drugs can also cause mild scarring fibres in the marrow.26Modern Pathology. Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities After stem cell transplant, people with more megakaryocytes in the marrow tended to respond faster to these drugs.27PubMed. Thrombopoietin receptor agonists for refractory thrombocytopenia in patients after autologous hematopoietic stem cell transplantation
Because giant, heavily lobed cells and mild scarring both appear in MPNs, a pathologist who doesn’t know about the drug could draw the wrong conclusion. Gene tests for the driver genes help separate the two, since a drug effect does not produce those mutations, though a negative result does not rule out an MPN on its own.
Before a biopsy, list every platelet-raising drug and the date you started it. Mention recent iron supplements or infections, since both can shift the marrow’s response. Bring earlier blood counts so the trend over time can be seen alongside the biopsy.
Why Abnormal Megakaryocytes Can Scar the Marrow
Megakaryocytes normally make growth factors that platelets carry to injured tissue to help repair it.28PubMed Central. Megakaryocyte Contribution to Bone Marrow Fibrosis: many Arrows in the Quiver In myelofibrosis, the abnormal cells and their platelets release these signals in excess, driving scarring.29PubMed Central. Fibrosis and bone marrow: understanding causation and pathobiology One of them triggers scarring in many organs and is concentrated in these cells in myelofibrosis.30PubMed. Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis The signals push nearby support cells to lay down fibres, which gradually replace normal marrow space. Over time, scarring crowds out normal blood making, causing anaemia and a big spleen, since the spleen takes over some of the work and enlarges.
The process is slow, so reports grade fibrosis rather than calling it present or absent, commonly on a scale from MF-0 to MF-3, with higher numbers meaning more scarring. Mild grades can occur with drugs or reactive states, so a low grade alone does not mean myelofibrosis. Higher grades, together with the typical cell pattern and gene findings, point toward it.
Tests That Pinpoint the Cause
A full blood count with platelet size helps separate destruction from reactive or cancer causes.31PubMed. The relation of megakaryocyte ploidy to platelet volume Iron and inflammation tests check for reactive causes. Blood or marrow testing for JAK2, CALR and MPL looks for an MPN.32MPN Research Foundation. Essential Thrombocythemia (ET) On the biopsy itself, special stains highlight megakaryocytes.33PubMed. von Willebrand factor is the most reliable immunohistochemical marker for megakaryocytes of myelodysplastic syndrome and chronic myeloproliferative disorders
Biopsy results usually take one to two weeks, and gene results may arrive separately. A haematologist then reviews everything together, since no single result settles the cause. Repeat blood counts may be needed to see whether the numbers settle, particularly if a reactive cause is being treated.
Useful questions for that appointment: Does the pattern look reactive or neoplastic? Were driver mutations found? Is there any scarring, and what grade? Do I need clot prevention?
In children, rare variants in the gene for the platelet hormone, or for the receptor it acts on, cause inherited low platelets, and severe forms can lead to marrow failure. Any family history should be mentioned.